Background Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce
alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD) …

Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …

Abstract Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1
(Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) …

Although the multifaceted mechanisms underlying alcohol use disorder (AUD) have been
partially defined, the neurobiological complexity of this disorder is yet to be unraveled. One …

Alcohol use disorder (AUD) is a chronic relapsing condition characterized by compulsive
alcohol-seeking behaviors, with serious detrimental health consequences. Despite high …

Background Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts
for 5% of deaths annually, and there is an urgent need to develop new targets for …

Cannabis is the most frequently used illicit drug in the United States with more than 45
million users of whom one-third suffer from a cannabis use disorder (CUD). Despite its high …

Alcohol and substance use disorders (AUD, SUD) have diverse systemic and
neuroinflammatory mechanisms. Existing approved pharmacotherapies for AUD/SUDs are …

Abstract Glucagon-like peptide 1 (GLP-1), an incretin hormone that reduces food intake, was
recently established as a novel regulator of alcohol-mediated behaviors. Clinically available …

Background Preclinical studies in rodents have demonstrated inhibitory effects of glucagon-
like peptide-1 (GLP-1) receptor stimulation on alcohol consumption. The effects of GLP-1 …